Literature DB >> 9024706

Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC.

K Tarao1, S Takemiya, S Tamai, Y Sugimasa, S Ohkawa, M Akaike, H Tanabe, A Shimizu, M Yoshida, A Kakita.   

Abstract

BACKGROUND: The relationship between the recurrence of hepatocellular carcinoma (HCC) and the serum alanine aminotransferase (ALT) level was studied in hepatectomized patients with hepatitis C virus (HCV)-associated cirrhosis and HCC.
METHODS: Twenty-six hepatectomized patients with HCV-associated cirrhosis and HCC whose resected specimens showed neither portal vein nor hepatic vein invasion by HCC histologically were divided into 2 groups: 15 patients who had no recurrence 3 years after surgery (Group A) and 11 patients whose disease recurred 1-3 years after surgery (Group B). The patients' serum ALT levels during this period were examined.
RESULTS: In Group A, serum ALT generally showed sustained low levels < 80 international units (INU) in 12 patients (80%). In contrast, ALT levels in Group B showed several peaks or plateaus > 80 INU in all patients except 2. The recurrence rate of HCC in the hepatectomized patients with sustained low levels of ALT was 14.3% (2 of 14 patients) at 3 years, and was significantly lower (P < 0.01) than that in those patients whose ALT levels showed several peaks or plateaus > 80 INU (9 of 12 patients; 75.0%). The average level of mode of ALT in Group A (48.8 +/- 26.0 INU) was significantly smaller than that in Group B (101.1 +/- 47.3 INU) (P < 0.005).
CONCLUSIONS: The importance of hepatocytic necrosis in the recurrence of HCC in hepatectomized patients with cirrhosis and HCC of HCV origin was demonstrated and the significance of subsiding hepatic necroinflammatory process in the prevention of HCC recurrence suggested.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024706     DOI: 10.1002/(sici)1097-0142(19970215)79:4<688::aid-cncr5>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

Review 1.  Treatment of hepatocarcinoma.

Authors:  Beatrice Gerard; Harry Bleiberg
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

2.  Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety.

Authors:  Y Nakamoto; E Mizukoshi; H Tsuji; Y Sakai; M Kitahara; K Arai; T Yamashita; K Yokoyama; N Mukaida; K Matsushima; O Matsui; S Kaneko
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection.

Authors:  Takashi Kumada; Hidenori Toyoda; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Junji Kondo; Takahiro Yamauchi; Satoshi Nakano
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

4.  Prevention of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

5.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

6.  Strain elastography for assessment of liver fibrosis and prognosis in patients with chronic liver diseases.

Authors:  Kazuto Tajiri; Kengo Kawai; Toshiro Sugiyama
Journal:  J Gastroenterol       Date:  2016-10-27       Impact factor: 7.527

Review 7.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

8.  Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma.

Authors:  Takahiro Ezaki; Toru Ikegami; Takashi Maeda; Tomomi Yamada; Teruyoshi Ishida; Makoto Hashizume; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2005-06       Impact factor: 3.402

Review 9.  Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

10.  Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns.

Authors:  Yusuke Okuwaki; Takahide Nakazawa; Akitaka Shibuya; Koji Ono; Hisashi Hidaka; Masaaki Watanabe; Shigehiro Kokubu; Katsunori Saigenji
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.